Tofacitinib (CP690550; tasocitinib)

Description: Tofacitinib (also known as tasocitinib or CP-690550, sold under the brand Xeljanz), is a novel and potent inhibitor of JAK3 (Janus-Associated kinase) with potential anti-inflammatory activity. It inhibits JAK1, JAK2, and JAK3 with IC50s of 1.0 nM, 21.7 nM, and 6.5 nM, respectively, in cell-free assays. It is an FDA approved drug for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis. The inhibition is JAK3-specific with a selectivity of 1000-fold higher than other non-JAK family kinases.

References: J Med Chem. 2010 Dec 23; 53(24):8468-84; Cancer Sci. 2008 Jun; 99(6):1265-73; J Leukoc Biol. 2004 Dec; 76(6):1248-55.

Related CAS: 2052885-67-1 (maleate); 540737-29-9 (citrate); 1092578-47-6 (3S, 4S)-Tofacitinib; 1443435-54-8 (oxalate); 1092578-48-7 (3S, 4R)-Tofacitinib; 1443435-50-4 (tartrate); 1092578-46-5 (3R, 4S)-Tofacitinib; 1259404-17-5 (Tofacitinib racemate); 477600-75-2 (free base); 1803005-18-6 (HCl); 1803005-19-7 (HBr);

CP-690550; CP690550; CP 690550; Tasocitinib; Tofacitinib; Xeljanz (Trade name); Tofacitinib free base;

Chemical Name: 3-((3R, 4R)-4-Methyl-3-(methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

SMILES Code: N#CCC(N1C[CH](N(C)C2=C3C(NC=C3)=NC=N2)[CH](C)CC1)=O

Exact Mass: 312.16986